Alexandre Ambrogelly
Overview
Explore the profile of Alexandre Ambrogelly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
991
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ambrogelly A
Antibodies (Basel)
. 2021 Jun;
10(2).
PMID: 34073775
The color of a therapeutic monoclonal antibody solution is a critical quality attribute. Consistency of color is typically assessed at time of release and during stability studies against preset criteria...
2.
Valeich J, Boyd D, Kanwar M, Stenzel D, De Ghosh D, Ebrahimi A, et al.
Antibodies (Basel)
. 2020 Sep;
9(4).
PMID: 32977708
A variety of Fc domain engineering approaches for abrogating the effector functions of mAbs exists. To address some of the limitations of the current Fc domain silencing approaches, we are...
3.
Boyd D, Ebrahimi A, Ronan S, Mickus B, Schenauer M, Wang J, et al.
MAbs
. 2018 Mar;
10(3):346-353.
PMID: 29537936
Isolation and characterization of monoclonal antibody (mAb) variants to understand the impact of their structure on function is a typical activity during early-stage candidate selection that contributes to derisking clinical...
4.
Ambrogelly A, Gozo S, Katiyar A, Dellatore S, Kune Y, Bhat R, et al.
MAbs
. 2018 Mar;
10(4):513-538.
PMID: 29513619
Process changes are inevitable in the life cycle of recombinant monoclonal antibody therapeutics. Products made using pre- and post-change processes are required to be comparable as demonstrated by comparability studies...
5.
Wang J, Stenzel D, Liu A, Liu D, Brown D, Ambrogelly A
Anal Biochem
. 2018 Jan;
545:65-71.
PMID: 29339060
Therapeutic vaccines represent an emerging class of immune-modulatory treatments for cancer, infections, and chronic diseases. One such vaccine was designed as an immune stimulator of the T cell response against...
6.
Yang X, Kim S, Ruzanski R, Chen Y, Moses S, Ling W, et al.
MAbs
. 2016 Apr;
8(4):706-17.
PMID: 27082290
Glycosylation is a critical attribute for development and manufacturing of therapeutic monoclonal antibodies (mAbs) in the pharmaceutical industry. Conventional antibody glycan analysis is usually achieved by the 2-aminobenzamide (2-AB) hydrophilic...
7.
Yang X, Wang F, Zhang Y, Wang L, Antonenko S, Zhang S, et al.
J Pharm Sci
. 2015 Aug;
104(12):4002-4014.
PMID: 26308749
IgG4 antibodies are evolving as an important class of cancer immunotherapies. However, human IgG4 can undergo Fab arm (half molecule) exchange with other IgG4 molecules in vivo. The hinge modification...
8.
Yang X, Zhang Y, Wang F, Wang L, Richardson D, Shameem M, et al.
Anal Biochem
. 2015 Jun;
484:173-9.
PMID: 26091837
Therapeutic non-hinge-modified IgG4 molecules form bispecific hybrid antibodies with endogenous human IgG4 molecules via a process known as Fab-arm exchange (or called half molecule exchange). Analysis of the bispecific hybrids...
9.
Yang X, Ambrogelly A
Curr Opin Biotechnol
. 2014 Sep;
30:225-9.
PMID: 25254943
Half molecule exchange is the process whereby two IgG4 molecules exchange a heavy chain-light chain unit to form a new IgG4 entity with specificity towards two different antigens. While this...
10.
Haverick M, Mengisen S, Shameem M, Ambrogelly A
MAbs
. 2014 Apr;
6(4):852-8.
PMID: 24751784
Hydrophobic interaction chromatography-high performance liquid chromatography (HIC-HPLC) is a powerful analytical method used for the separation of molecular variants of therapeutic proteins. The method has been employed for monitoring various...